IL-18BP, His, Cynomolgus
IL-18BP, His, Cynomolgus

Immobilized Human IL-18, No Tag at 1 μg/ml(100 μl/well) on the plate. Dose response curve for IL-18BP, His, Cynomolgus, His Tag with the EC50 of 4.5 ng/ml determined by ELISA.

IL-18BP, His, Cynomolgus

IL-18BP, His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

IL-18BP, His, Cynomolgus

Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer, components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice
Z04831
¥72,752.00

Ask us a question
Product Introduction
Species Cynomolgus
Protein Construction
IL-18BP (Thr28-Pro207)
Accession # A0A2K5UDJ4		 His
N-term C-term
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 1 EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 21.14 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 35-65 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • IL-18BP, His, Cynomolgus
    • IL-18BP, His, Cynomolgus

    Immobilized Human IL-18, No Tag at 1 μg/ml(100 μl/well) on the plate. Dose response curve for IL-18BP, His, Cynomolgus, His Tag with the EC50 of 4.5 ng/ml determined by ELISA.

  • IL-18BP, His, Cynomolgus
    • IL-18BP, His, Cynomolgus

    IL-18BP, His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer, components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice
Synonyms IL-18BP; Igifbp; Interleukin-18-binding protein

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.